Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Biocon arm gets Health Canada nod for fungal infection treatment injection
Biocon Pharma Ltd has secured Health Canada approval for its micafungin for injection. This medication targets serious fungal infections in adults and children. It will be used for conditions like candidemia and esophageal candidiasis. The approval also covers prophylaxis in stem cell transplant patients. This marks a significant addition to Biocon's product offerings.
Biocon shares gain after Health Canada approval for injection used in treating bloodstream infections
Biocon gets Health Canada nod for micafungin injection, which is indicated for use in adults and children four months and older for treatment of patients with Candidemia. The market size of the said injection has not been disclosed.
Biosimilar ramp-up to drive growth for Biocon in FY27
Recently launched biosimilars across markets have begun scaling up and will gather momentum through the year, particularly in the second half of FY27, the company's top executive said
Biocon shifts focus to margins, capacity utilisation after expansion phase
Biocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in global capabilities. The company reported a 13% revenue increase for FY26, though net profit saw a substantial decline. Biocon is also prioritizing sustainable, profitable growth and exploring in-licensing opportunities for its biosimilars portfolio.
Biocon reports 63% YoY fall in Q4 profit, final dividend of Rs. 0.50 recommended
Biocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges impacting the company's financials. However, core businesses demonstrated growth. The company successfully integrated its biosimilars and generics operations. This strategic move aims to enhance scale and market reach. Biocon is now focused on improving profitability and creating long-term value for shareholders.
Biocon Ltd soars 1.16%, gains for fifth straight session
Biocon Ltd is quoting at Rs 386.7, up 1.16% on the day as on 12:44 IST on the NSE. The stock is up 17.22% in last one year as compared to a 0.65% jump in NIFTY and a 14.52% jump in the Nifty Pharma.
Biocon posts PAT of Rs 126 crore in Q4 FY26; EBIDTA margin stands at 23%
Biocon has reported 63.4% drop in consolidated net profit to Rs 126 crore in Q4 FY26 from Rs 344 crore in Q4 FY25.
Biocon Q4 Results: Net profit down 57% at Rs 198.6 crore
Biocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolidated revenue grew to Rs 4,516.6 crore. For FY26, net profit declined to Rs 368.8 crore, though revenue rose to Rs 16,927 crore.
Biocon Shares Rally Despite Net Profit Falling Over 60% In Q4 Earnings — Here's Why
Although the profitability dipped considerably in Q4, it was largely due to a high base effect, as Q4FY25 had benefitted fromelevated generic lenalidomide sales.
Biocon shares gain 3% despite 57% drop in Q4 profit; dividend announced
Bengaluru-based Biocon said that its Q4 profit stood at ₹198.6. The profit was hit by an exceptional item outgo of ₹80.4 crore on various heads, including the impact of the new labour code.
Biocon Q4 Results: Net Profit Plunges 63% On High Base, Exceptional Item
The sharp decline in profit was largely a function of a high base effect, as Q4FY25 had benefitted from elevated genericlenalidomide sales and the impact of an exceptional in the current quarter.
Promoter Shareholding: Godrej Properties, Adani Energy see stake hike; BHEL, Vishal Mega Mart, Biocon face cuts
Promoter Shareholding: The companies that recorded an increase in promoter ownership between the December 2025 and March 2026, Godrej Properties saw promoter holding rise from 47.2% to 51.7%, while Adani Energy Solutions witnessed an increase from 71.2% to 72.7%.